

7th August 2025

FOR PUBLIC RELEASE

Rua Bioscience receives capital from existing shareholders to support significant sales growth

Tairawhiti, New Zealand – Rua Bioscience is pleased to announce it has secured a total of \$1.2 million in new funding through a combination of equity and existing lending instruments. This capital has been provided by several key shareholders, reflecting their continued confidence in Rua's vision and strategic direction.

Today, the Board resolved to issue up to 16,000,000 new ordinary shares at an issue price of \$0.03 per share. These equity securities will be issued under the company's existing placement capacity.

The funds raised will be used to accelerate sales growth in our key markets of Germany, Australia, New Zealand and the UK, and support near-term working capital requirements.

This investment represents a strong endorsement of Rua's strategy by key shareholders as we continue to introduce our unique genetics from Te Tairawhiti to patients around the world

ENDS

The person who authorised this announcement:

Paul Naske

Chief Executive Officer

paul.naske@ruabio.com

+64 21 445154